Symbols / SLNO Stock $52.75 +0.06% Soleno Therapeutics, Inc.
SLNO (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-17 | down | Wells Fargo | Overweight → Equal-Weight | $53 |
| 2026-04-08 | down | HC Wainwright & Co. | Buy → Neutral | $53 |
| 2026-04-07 | down | TD Cowen | Buy → Hold | $53 |
| 2026-04-07 | down | Wolfe Research | Outperform → Peer Perform | — |
| 2026-04-06 | down | Cantor Fitzgerald | Overweight → Neutral | $53 |
| 2026-03-18 | main | Oppenheimer | Outperform → Outperform | $80 |
| 2026-03-04 | main | HC Wainwright & Co. | Buy → Buy | $100 |
| 2026-02-27 | main | Wells Fargo | Overweight → Overweight | $110 |
| 2026-02-26 | main | TD Cowen | Buy → Buy | $85 |
| 2026-01-20 | main | Wells Fargo | Overweight → Overweight | $114 |
| 2026-01-20 | main | HC Wainwright & Co. | Buy → Buy | $120 |
| 2025-11-18 | init | Wolfe Research | — → Outperform | $75 |
| 2025-11-05 | main | Wells Fargo | Overweight → Overweight | $106 |
| 2025-08-27 | reit | Guggenheim | Buy → Buy | $106 |
| 2025-08-20 | init | Wells Fargo | — → Overweight | $123 |
| 2025-08-18 | main | HC Wainwright & Co. | Buy → Buy | $110 |
| 2025-08-07 | main | Guggenheim | Buy → Buy | $106 |
| 2025-08-07 | main | Oppenheimer | Outperform → Outperform | $110 |
| 2025-07-11 | main | Baird | Outperform → Outperform | $121 |
| 2025-05-08 | main | Guggenheim | Buy → Buy | $97 |
- Why is SLNO stock surging over 20% overnight? - MSN Mon, 27 Apr 2026 17
- SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman - Morningstar Mon, 27 Apr 2026 22
- SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman - ChartMill Mon, 27 Apr 2026 22
- SLNO SEC Filings - Soleno Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan Mon, 27 Apr 2026 17
- SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire Mon, 27 Apr 2026 18
- Deadline Alert: Soleno Therapeutics, Inc. (SLNO) - GlobeNewswire Mon, 27 Apr 2026 17
- Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com Mon, 06 Apr 2026 07
- SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - ChartMill Mon, 27 Apr 2026 18
- SLNO stock soars over 39% — what’s fueling the rally? - MSN Mon, 27 Apr 2026 13
- Soleno Therapeutics Inc (NASDAQ:SLNO): A Decent Value Play with Strong Health and Explosive Growth Potential - ChartMill Mon, 27 Apr 2026 11
- SLNO Deadline: Rosen Law Firm Urges Soleno Therapeutics, Inc. (NASDAQ: SLNO) Stockholders to Contact the Firm for Information About Their Rights - ChartMill Mon, 27 Apr 2026 15
- BlackRock (NYSE: BLK) reports 3.54M shares, 6.9% of Soleno (SLNO) - Stock Titan Fri, 24 Apr 2026 20
- INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman - ChartMill hu, 23 Apr 2026 21
- Down 18.3% in 4 weeks, here's why Soleno Therapeutics (SLNO) looks ripe for a turnaround - MSN Sun, 26 Apr 2026 17
- Soleno Therapeutics (SLNO) Still Appears Attractive Despite Slower U.S. Launch Ramp Projections - Yahoo Finance Wed, 01 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
190.41
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
190.41
|
0.00
|
0.00
|
0.00
|
| Cost Of Revenue |
|
2.70
|
0.00
|
0.00
|
—
|
| Reconciled Cost Of Revenue |
|
2.70
|
0.00
|
0.00
|
—
|
| Gross Profit |
|
187.71
|
0.00
|
0.00
|
—
|
| Operating Expense |
|
172.75
-6.33%
|
184.43
+376.93%
|
38.67
+54.01%
|
25.11
|
| Research And Development |
|
40.63
-48.29%
|
78.57
+211.91%
|
25.19
+65.01%
|
15.27
|
| Selling General And Administration |
|
132.13
+24.81%
|
105.86
+685.26%
|
13.48
+36.95%
|
9.84
|
| General And Administrative Expense |
|
—
|
105.86
+685.26%
|
13.48
+36.95%
|
9.84
|
| Other Gand A |
|
—
|
105.86
+685.26%
|
13.48
+36.95%
|
9.84
|
| Total Expenses |
|
175.46
-4.87%
|
184.43
+376.93%
|
38.67
+54.01%
|
25.11
|
| Operating Income |
|
14.95
+108.11%
|
-184.43
-376.93%
|
-38.67
-54.01%
|
-25.11
|
| Total Operating Income As Reported |
|
9.41
+105.02%
|
-187.67
-353.49%
|
-41.38
-69.63%
|
-24.40
|
| EBITDA |
|
28.38
+116.35%
|
-173.63
-368.90%
|
-37.03
-67.53%
|
-22.10
|
| Normalized EBITDA |
|
33.92
+119.91%
|
-170.39
-399.18%
|
-34.13
-49.42%
|
-22.84
|
| Reconciled Depreciation |
|
2.02
+1.51%
|
1.99
+1.48%
|
1.96
-0.31%
|
1.96
|
| EBIT |
|
26.37
+115.01%
|
-175.62
-350.44%
|
-38.99
-62.00%
|
-24.07
|
| Total Unusual Items |
|
-5.54
-70.76%
|
-3.24
-11.95%
|
-2.90
-490.30%
|
0.74
|
| Total Unusual Items Excluding Goodwill |
|
-5.54
-70.76%
|
-3.24
-11.95%
|
-2.90
-490.30%
|
0.74
|
| Special Income Charges |
|
-5.54
-70.76%
|
-3.24
-19.45%
|
-2.71
-481.18%
|
0.71
|
| Restructuring And Mergern Acquisition |
|
5.54
+70.76%
|
3.24
+19.45%
|
2.71
+481.18%
|
-0.71
|
| Net Income |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Pretax Income |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Net Non Operating Interest Income Expense |
|
11.48
-2.92%
|
11.82
+358.53%
|
2.58
+759.33%
|
0.30
|
| Interest Expense Non Operating |
|
5.48
+2270.56%
|
0.23
|
0.00
|
0.00
|
| Net Interest Income |
|
11.48
-2.92%
|
11.82
+358.53%
|
2.58
+759.33%
|
0.30
|
| Interest Expense |
|
5.48
+2270.56%
|
0.23
|
0.00
|
0.00
|
| Interest Income Non Operating |
|
16.95
+40.66%
|
12.05
+367.49%
|
2.58
+759.33%
|
0.30
|
| Interest Income |
|
16.95
+40.66%
|
12.05
+367.49%
|
2.58
+759.33%
|
0.30
|
| Other Income Expense |
|
-5.54
-70.76%
|
-3.24
-11.95%
|
-2.90
-490.30%
|
0.74
|
| Gain On Sale Of Security |
|
—
|
—
|
-0.18
-706.67%
|
0.03
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Net Income From Continuing Operation Net Minority Interest |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Net Income From Continuing And Discontinued Operation |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Net Income Continuous Operations |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Normalized Income |
|
26.43
+115.31%
|
-172.61
-378.24%
|
-36.09
-45.48%
|
-24.81
|
| Net Income Common Stockholders |
|
20.48
+111.64%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Otherunder Preferred Stock Dividend |
|
0.41
|
0.00
|
0.00
|
—
|
| Diluted EPS |
|
0.39
+108.90%
|
-4.38
-85.59%
|
-2.36
+17.77%
|
-2.87
|
| Basic EPS |
|
0.40
+109.13%
|
-4.38
-85.59%
|
-2.36
+17.77%
|
-2.87
|
| Basic Average Shares |
|
50.82
+26.49%
|
40.18
+143.61%
|
16.49
+96.40%
|
8.40
|
| Diluted Average Shares |
|
52.38
+30.39%
|
40.18
+143.61%
|
16.49
+96.40%
|
8.40
|
| Diluted NI Availto Com Stockholders |
|
20.48
+111.64%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
563.83
+70.36%
|
330.97
+83.17%
|
180.69
+581.93%
|
26.50
|
| Current Assets |
|
355.81
+21.07%
|
293.89
+71.51%
|
171.36
+995.15%
|
15.65
|
| Cash Cash Equivalents And Short Term Investments |
|
305.47
+4.82%
|
291.44
+71.76%
|
169.68
+1062.04%
|
14.60
|
| Cash And Cash Equivalents |
|
70.11
-20.27%
|
87.93
-48.18%
|
169.68
+1062.04%
|
14.60
|
| Other Short Term Investments |
|
235.37
+15.65%
|
203.51
|
0.00
|
—
|
| Receivables |
|
28.21
|
0.00
|
—
|
—
|
| Accounts Receivable |
|
28.21
|
0.00
|
—
|
—
|
| Inventory |
|
15.02
|
0.00
|
—
|
—
|
| Raw Materials |
|
6.45
|
0.00
|
—
|
—
|
| Work In Process |
|
2.71
|
0.00
|
—
|
—
|
| Finished Goods |
|
6.02
|
0.00
|
—
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
7.11
+189.97%
|
2.45
+46.21%
|
1.68
+60.48%
|
1.04
|
| Total Non Current Assets |
|
208.02
+460.95%
|
37.08
+297.33%
|
9.33
-13.98%
|
10.85
|
| Net PPE |
|
2.38
-20.38%
|
2.98
+612.17%
|
0.42
+166.88%
|
0.16
|
| Gross PPE |
|
2.50
-18.17%
|
3.05
+501.18%
|
0.51
+118.97%
|
0.23
|
| Accumulated Depreciation |
|
-0.12
-75.71%
|
-0.07
+21.35%
|
-0.09
-18.67%
|
-0.07
|
| Properties |
|
0.00
|
0.00
|
0.00
|
—
|
| Machinery Furniture Equipment |
|
0.21
+5.39%
|
0.20
+101.98%
|
0.10
+0.00%
|
0.10
|
| Other Properties |
|
2.19
-21.69%
|
2.80
+587.47%
|
0.41
+210.69%
|
0.13
|
| Leases |
|
0.09
+78.85%
|
0.05
|
0.00
|
—
|
| Goodwill And Other Intangible Assets |
|
4.86
-28.57%
|
6.80
-22.22%
|
8.75
-18.18%
|
10.69
|
| Other Intangible Assets |
|
4.86
-28.57%
|
6.80
-22.22%
|
8.75
-18.18%
|
10.69
|
| Investments And Advances |
|
200.62
+637.26%
|
27.21
|
0.00
|
—
|
| Other Non Current Assets |
|
0.16
+96.39%
|
0.08
-49.70%
|
0.17
|
—
|
| Total Liabilities Net Minority Interest |
|
113.72
+32.44%
|
85.86
+270.34%
|
23.18
+43.56%
|
16.15
|
| Current Liabilities |
|
61.36
+227.32%
|
18.75
+62.95%
|
11.51
+57.32%
|
7.31
|
| Payables And Accrued Expenses |
|
16.55
+23.09%
|
13.45
+105.52%
|
6.54
+30.87%
|
5.00
|
| Payables |
|
12.44
+40.00%
|
8.88
+182.06%
|
3.15
+77.21%
|
1.78
|
| Accounts Payable |
|
12.44
+40.00%
|
8.88
+182.06%
|
3.15
+77.21%
|
1.78
|
| Current Accrued Expenses |
|
4.11
-9.84%
|
4.56
+34.48%
|
3.39
+5.31%
|
3.22
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
9.68
+102.62%
|
4.78
+52.34%
|
3.13
+87.16%
|
1.68
|
| Current Debt And Capital Lease Obligation |
|
0.73
+38.02%
|
0.53
+92.67%
|
0.27
+76.13%
|
0.15
|
| Current Capital Lease Obligation |
|
0.73
+38.02%
|
0.53
+92.67%
|
0.27
+76.13%
|
0.15
|
| Other Current Liabilities |
|
20.38
+644.61%
|
2.74
+76.01%
|
1.55
+221.28%
|
0.48
|
| Total Non Current Liabilities Net Minority Interest |
|
52.35
-21.99%
|
67.11
+474.64%
|
11.68
+32.18%
|
8.84
|
| Long Term Debt And Capital Lease Obligation |
|
51.83
-0.90%
|
52.30
+40130.77%
|
0.13
|
0.00
|
| Long Term Debt |
|
49.86
+0.07%
|
49.83
|
—
|
—
|
| Long Term Capital Lease Obligation |
|
1.96
-20.55%
|
2.47
+1801.54%
|
0.13
|
0.00
|
| Other Non Current Liabilities |
|
0.53
-96.46%
|
14.81
+28.25%
|
11.55
+30.72%
|
8.84
|
| Stockholders Equity |
|
450.12
+83.64%
|
245.11
+55.62%
|
157.51
+1422.10%
|
10.35
|
| Common Stock Equity |
|
450.12
+83.64%
|
245.11
+55.62%
|
157.51
+1422.10%
|
10.35
|
| Capital Stock |
|
0.05
+13.04%
|
0.05
+43.75%
|
0.03
+300.00%
|
0.01
|
| Common Stock |
|
0.05
+13.04%
|
0.05
+43.75%
|
0.03
+300.00%
|
0.01
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
52.29
+14.40%
|
45.70
+44.28%
|
31.68
+288.24%
|
8.16
|
| Ordinary Shares Number |
|
52.29
+14.40%
|
45.70
+44.28%
|
31.68
+288.24%
|
8.16
|
| Additional Paid In Capital |
|
881.02
+26.41%
|
696.97
+60.63%
|
433.88
+75.12%
|
247.76
|
| Retained Earnings |
|
-431.37
+4.62%
|
-452.26
-63.62%
|
-276.41
-16.42%
|
-237.42
|
| Gains Losses Not Affecting Retained Earnings |
|
0.41
+14.96%
|
0.36
|
0.00
|
—
|
| Other Equity Adjustments |
|
0.41
+14.96%
|
0.36
|
—
|
—
|
| Total Equity Gross Minority Interest |
|
450.12
+83.64%
|
245.11
+55.62%
|
157.51
+1422.10%
|
10.35
|
| Total Capitalization |
|
499.98
+69.52%
|
294.94
+87.26%
|
157.51
+1422.10%
|
10.35
|
| Working Capital |
|
294.45
+7.02%
|
275.14
+72.12%
|
159.85
+1818.08%
|
8.33
|
| Invested Capital |
|
499.98
+69.52%
|
294.94
+87.26%
|
157.51
+1422.10%
|
10.35
|
| Total Debt |
|
52.55
-0.52%
|
52.83
+13008.19%
|
0.40
+160.00%
|
0.15
|
| Capital Lease Obligations |
|
2.69
-10.27%
|
3.00
+643.92%
|
0.40
+160.00%
|
0.15
|
| Net Tangible Assets |
|
445.25
+86.84%
|
238.31
+60.20%
|
148.76
+43218.26%
|
-0.34
|
| Tangible Book Value |
|
445.25
+86.84%
|
238.31
+60.20%
|
148.76
+43218.26%
|
-0.34
|
| Available For Sale Securities |
|
200.62
+637.26%
|
27.21
|
—
|
—
|
| Current Provisions |
|
14.03
|
—
|
—
|
—
|
| Derivative Product Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Interest Payable |
|
0.40
|
0.00
|
—
|
—
|
| Inventories Adjustments Allowances |
|
-0.16
|
0.00
|
—
|
—
|
| Investmentin Financial Assets |
|
200.62
+637.26%
|
27.21
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
46.80
+167.73%
|
-69.10
-177.05%
|
-24.94
-20.01%
|
-20.78
|
| Cash Flow From Continuing Operating Activities |
|
46.80
+167.73%
|
-69.10
-177.05%
|
-24.94
-20.01%
|
-20.78
|
| Net Income From Continuing Operations |
|
20.89
+111.88%
|
-175.85
-351.04%
|
-38.99
-62.00%
|
-24.07
|
| Depreciation Amortization Depletion |
|
2.02
+1.51%
|
1.99
+1.48%
|
1.96
-0.31%
|
1.96
|
| Depreciation And Amortization |
|
2.02
+1.51%
|
1.99
+1.48%
|
1.96
-0.31%
|
1.96
|
| Other Non Cash Items |
|
6.20
+68.07%
|
3.69
+21.45%
|
3.04
+819.19%
|
-0.42
|
| Stock Based Compensation |
|
45.85
-54.13%
|
99.96
+1581.38%
|
5.95
+134.98%
|
2.53
|
| Operating Gains Losses |
|
—
|
—
|
0.18
+706.67%
|
-0.03
|
| Gain Loss On Investment Securities |
|
—
|
—
|
0.18
+706.67%
|
-0.03
|
| Change In Working Capital |
|
-24.63
-509.32%
|
6.02
+105.53%
|
2.93
+487.30%
|
-0.76
|
| Change In Receivables |
|
-28.21
|
0.00
|
0.00
|
—
|
| Changes In Account Receivables |
|
-28.21
|
0.00
|
0.00
|
—
|
| Change In Inventory |
|
-14.03
|
0.00
|
0.00
|
—
|
| Change In Prepaid Assets |
|
-4.74
-531.73%
|
-0.75
+10.39%
|
-0.84
-840.71%
|
0.11
|
| Change In Payables And Accrued Expense |
|
8.51
+16.41%
|
7.31
+158.23%
|
2.83
+489.01%
|
-0.73
|
| Change In Accrued Expense |
|
4.90
+198.66%
|
1.64
+12.40%
|
1.46
+94.93%
|
0.75
|
| Change In Payable |
|
3.61
-36.32%
|
5.67
+313.41%
|
1.37
+192.89%
|
-1.48
|
| Change In Account Payable |
|
3.61
-36.32%
|
5.67
+313.41%
|
1.37
+192.89%
|
-1.48
|
| Change In Other Working Capital |
|
—
|
—
|
1.46
+54.17%
|
0.95
|
| Change In Other Current Liabilities |
|
13.83
+2637.80%
|
-0.55
-158.41%
|
0.93
+761.70%
|
-0.14
|
| Investing Cash Flow |
|
-201.78
+10.59%
|
-225.68
|
0.00
+100.00%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-201.78
+10.59%
|
-225.68
|
0.00
+100.00%
|
-0.01
|
| Net PPE Purchase And Sale |
|
-0.07
+66.51%
|
-0.22
|
0.00
+100.00%
|
-0.01
|
| Purchase Of PPE |
|
-0.07
+66.51%
|
-0.22
|
0.00
+100.00%
|
-0.01
|
| Capital Expenditure |
|
-0.07
+66.51%
|
-0.22
|
—
|
-0.01
|
| Net Investment Purchase And Sale |
|
-201.71
+10.54%
|
-225.46
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-455.78
-27.86%
|
-356.46
|
0.00
|
0.00
|
| Sale Of Investment |
|
254.07
+93.95%
|
131.00
|
0.00
|
0.00
|
| Financing Cash Flow |
|
137.16
-35.61%
|
213.03
+18.33%
|
180.02
+1177.46%
|
14.09
|
| Cash Flow From Continuing Financing Activities |
|
137.16
-35.61%
|
213.03
+18.33%
|
180.02
+1177.46%
|
14.09
|
| Net Issuance Payments Of Debt |
|
0.00
-100.00%
|
49.89
|
0.00
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
49.89
|
0.00
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
49.89
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
-100.00%
|
49.89
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
115.58
-22.41%
|
148.96
+8.05%
|
137.86
+877.15%
|
14.11
|
| Common Stock Payments |
|
-100.15
|
0.00
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
-100.15
|
0.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
22.39
+57.87%
|
14.18
-66.36%
|
42.16
|
0.00
|
| Net Other Financing Charges |
|
-0.80
|
—
|
—
|
-0.02
|
| Changes In Cash |
|
-17.82
+78.20%
|
-81.75
-152.72%
|
155.08
+2413.92%
|
-6.70
|
| Beginning Cash Position |
|
87.93
-48.18%
|
169.68
+1062.04%
|
14.60
-31.46%
|
21.30
|
| End Cash Position |
|
70.11
-20.27%
|
87.93
-48.18%
|
169.68
+1062.04%
|
14.60
|
| Free Cash Flow |
|
46.73
+167.41%
|
-69.31
-177.92%
|
-24.94
-19.94%
|
-20.79
|
| Interest Paid Supplemental Data |
|
4.53
+2069.38%
|
0.21
|
0.00
|
—
|
| Amortization Of Securities |
|
-3.52
+28.15%
|
-4.89
|
0.00
|
0.00
|
| Common Stock Issuance |
|
215.72
+44.82%
|
148.96
+8.05%
|
137.86
+877.15%
|
14.11
|
| Issuance Of Capital Stock |
|
215.72
+44.82%
|
148.96
+8.05%
|
137.86
+877.15%
|
14.11
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-07 View
- 8-K2026-04-06 View
- 42026-03-31 View
- 42026-03-31 View
- 8-K2026-03-16 View
- 42026-03-04 View
- 8-K2026-02-26 View
- 10-K2026-02-25 View
- 8-K2026-02-25 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 42026-01-23 View
- 8-K2026-01-23 View
- 8-K2026-01-12 View
- 42025-12-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|